Pathstone Holdings
DGX icon

Pathstone Holdings’s Quest Diagnostics DGX Stock Holding History

Pathstone Holdings’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.39M Sell
25,434
-6,243
-20% -$1.23M 0.02% 613
2026
Q1 		$6.21M Sell
31,677
-2,454
-7% -$477K 0.02% 494
2025
Q4 		$5.92M Sell
34,131
-41,037
-55% -$7.47M 0.02% 506
2025
Q3 		$14.3M Buy
75,168
+587
+0.8% +$104K 0.05% 237
2025
Q2 		$13.4M Sell
74,581
-89,740
-55% -$15.6M 0.05% 238
2025
Q1 		$27.8M Buy
164,321
+119,997
+271% +$19.7M 0.12% 127
2024
Q4 		$6.69M Buy
44,324
+1,683
+4% +$262K 0.03% 447
2024
Q3 		$6.62M Buy
42,641
+1,820
+4% +$272K 0.03% 464
2024
Q2 		$5.59M Sell
40,821
-24,583
-38% -$3.37M 0.03% 488
2024
Q1 		$8.71M Sell
65,404
-270,696
-81% -$35.1M 0.04% 337
2023
Q4 		$46.3M Buy
+336,100
New +$44.2M 0.25% 68

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Pathstone Holdings's DGX Position: Q2 2026 in Review

Pathstone Holdings reduced its Quest Diagnostics (DGX) stake by 20% in Q2 2026, selling an estimated $1.23M and leaving 25,434 shares worth $5.39M. The position accounts for 0.02% of the portfolio, ranked #613.

Pathstone Holdings first reported a position in DGX in Q4 2023 and has held it in 11 quarters since. The position peaked at $46.3M in Q4 2023. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Pathstone Holdings held 25,434 shares of Quest Diagnostics worth $5.39M as of Q2 2026.
  • Pathstone Holdings sold 6,243 Quest Diagnostics shares in Q2 2026, an estimated $1.23M.
  • Quest Diagnostics made up 0.02% of Pathstone Holdings's portfolio in Q2 2026, its #613 holding.
  • Pathstone Holdings first reported a position in Quest Diagnostics in Q4 2023 and has held it in 11 quarters since.
  • Pathstone Holdings's Quest Diagnostics position peaked at $46.3M in Q4 2023.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.